Research progress on the efficacy and safety of dupilumab in the treatment of allergic diseases
10.3760/cma.j.cn114015-20220307-00185
- VernacularTitle:度普利尤单抗治疗过敏性疾病有效性和安全性研究进展
- Author:
Wenjin DU
1
;
Rongfei ZHU
Author Information
1. 河南省人民医院/郑州大学人民医院过敏反应科，郑州 450003
- Publication Type:Journal Article
- Keywords:
Dermatitis, atopic;
Th2 cells;
Anaphylaxis;
Allergic diseases;
Dupilumab
- From:
Adverse Drug Reactions Journal
2022;24(10):540-545
- CountryChina
- Language:Chinese
-
Abstract:
Allergic diseases have serious influence on human health and quality of life. Cytokines secreted by T-helper cell type 2 (Th2), such as interleukin (IL)-4 and IL-13, play a pivotal role in the pathogenesis of allergic diseases. By recognizing and binding to IL-4 and IL-13 receptors, dupilumab can block the signal transduction pathways of IL-4 and IL-13, inhibit Th2 inflammatory reaction, and thus play a therapeutic role in allergic diseases. At present, dupilumab has been on the market in many countries and regions around the world, yet with different indications approved, mainly including atopic dermatitis, moderate-to-severe eosinophilic asthma, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, etc. In addition, this drug may also have better curative effect on IgE-mediated allergic reactions and other dermal diseases. Meanwhile, the safety profile of dupilumab is generally good and the common adverse reactions mainly include injection site reactions (pain, ecchymosis and swelling at the injection site), ocular diseases (conjunctivitis, keratitis, itchiness of eyes and dry eyes), oral herpes, headache, and other herpes simplex virus infections. In China, dupilumab has been approved for the treatment of moderate-to-severe atopic dermatitis in patients aged ≥6 years, showing good efficacy and no obvious safety problems.
